Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Tafasitamab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma
    Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210526828/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Incyte's Monjuvi proves its worth in follicular lymphoma
    Incyte's Monjuvi proves its worth in follicular lymphoma

    26 Nov 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/incytes-monjuvi-wins-big-follicular-lymphoma-phase-3-padding-upcoming-fda-filing

    FIERCE PHARMA
    26 Nov 2024
    Share Share
    Incyte to Present New Tafasitamab Data at 2024 ASH Annual Meeting
    Incyte to Present New Tafasitamab Data at 2024 ASH Annual Meeting

    25 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241125630696/en

    BUSINESSWIRE
    25 Nov 2024
    Share Share
    Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win
    Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win

    19 Aug 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/incyte-looks-widen-monjuvis-net-label-expansion-bid-after-phase-3-lymphoma-win

    FIERCE PHARMA
    19 Aug 2024
    Share Share
    Incyte Announces Positive Results From Tafasitamab Study In Follicular Lymphoma
    Incyte Announces Positive Results From Tafasitamab Study In Follicular Lymphoma

    15 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240815184197/en

    BUSINESSWIRE
    15 Aug 2024
    Share Share
    InnoCare's Tafasitamab BLA Accepted For DLBCL Treatment In China
    InnoCare's Tafasitamab BLA Accepted For DLBCL Treatment In China

    20 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240620164912/en

    BUSINESSWIRE
    20 Jun 2024
    Share Share